Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial ResultsPRNewsWire • 11/12/25
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury StrategyPRNewsWire • 11/12/25
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyPRNewsWire • 10/09/25
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyPRNewsWire • 10/06/25
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025PRNewsWire • 09/25/25
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesPRNewsWire • 06/23/25
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual MeetingPRNewsWire • 04/25/25
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerPRNewsWire • 04/15/25
Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptSeeking Alpha • 03/31/25
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal CancerBenzinga • 03/26/25
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyPRNewsWire • 03/26/25
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyPRNewsWire • 01/28/25
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon CancerSeeking Alpha • 01/06/25
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/06/25
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare ConferencePRNewsWire • 11/26/24
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsPRNewsWire • 09/30/24